Abstract
Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019
| Original language | English |
|---|---|
| Volume | September |
| State | Published - 2020 |
Publication series
| Name | Institute for New Economic Thinking (INET) |
|---|
